Minimal Residual Disease (MRD) follow up of MM patients obtaining stringent complete remission (sCR) in the NMSG/EMN02 clinical trial – defining sCR numbers and prediction of disease progression by multiparametric flow cytometry (MFC).

Hans Erik Johnsen, Karen Dybkær, Julie Støve Bødker et al.|VBN Forskningsportal (Aalborg Universitet)|2018

Cited by 0